Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
July 02, 2024 17:15 ET
|
Scilex Holding Company
Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA) (“SPAC”) announce signing of...
Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York
July 02, 2024 09:00 ET
|
Scilex Holding Company
The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO...
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
July 01, 2024 09:00 ET
|
Scilex Holding Company
ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year.ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%,...
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
June 20, 2024 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
June 14, 2024 13:41 ET
|
Scilex Holding Company
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for...
Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
June 13, 2024 09:00 ET
|
Scilex Holding Company
Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of...
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
June 11, 2024 19:20 ET
|
Scilex Holding Company
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®
June 11, 2024 09:00 ET
|
Scilex Holding Company
Scilex launched its third commercial product, GLOPERBA® on June 10, 2024.Scilex has officially shipped its recently approved, GLOPERBA® to many national drug/pharmacy chains, as well as independent...
Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.
June 10, 2024 11:49 ET
|
Scilex Holding Company
Stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S and Scilex expects completion of stocking by Wednesday June 12, 2024.Today,...
Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
June 06, 2024 14:56 ET
|
Scilex Holding Company
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting...